Related Experiment Video

Updated: Aug 8, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond

Robert S Warren1, David H Kirn

  • 1Department of Surgery, University of California-San Francisco, 533 Parnassus Avenue, U-372, San Francisco, CA 94143-0790, USA. warrenr@surgery.ucsf.edu

Surgical Oncology Clinics of North America
|December 19, 2002
PubMed

Insights

This review covers Phase I/II trials of adenovirus therapy for p53-deficient cancers using hepatic arterial infusion (HAI). Results show potential for regional adenovirus treatment in liver tumors.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Loss of p53 function is a common genetic alteration in human cancers.
  • Adenovirus vectors are being developed for p53-deficient cancer treatment.
  • Hepatic arterial infusion (HAI) is a method for targeting liver tumors.

Purpose of the Study:

  • To review Phase I and I/II clinical trial results.
  • To evaluate regional adenovirus therapy via HAI for p53-deficient cancers.
  • To assess the efficacy of replication-incompetent and replication-selective adenoviruses.

Main Methods:

  • Review of Phase I and I/II clinical trial data.
  • Analysis of hepatic arterial infusion (HAI) delivery of adenoviruses.
  • Evaluation of two adenovirus constructs: rAd.p53 (SCH58500) and dl1520 (Onyx-015).

Main Results:

  • Phase I/II trials investigated HAI with adenovirus constructs.
  • The study focuses on adenovirus treatment for p53-deficient cancers.
  • Results from HAI trials with SCH58500 and Onyx-015 are discussed.

Conclusions:

  • Regional adenovirus therapy via HAI is an attractive approach for liver tumors.
  • Adenovirus constructs show potential in treating p53-deficient cancers.
  • Further review of trial results is presented.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...